下肢动脉硬化闭塞症的药物治疗_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 时德

重庆医科大学附属第一医院血管外科重庆市血管外科中心（重庆 400016）;

Corresponding author：

时德, Email: sdpwqlsl@126.com

Keywords：

DOI：

10.7507/1007-9424.20150236

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 时德. 下肢动脉硬化闭塞症的药物治疗. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(8): 904-909. doi: 10.7507/1007-9424.20150236 Copy

1.	Liuzzo G. Atherosclerosis:an inflammatory disease. Rays, 2001, 26(4):221-230.
2.	Pappalardo F, Scandroglio AM, Potapov E, et al. Argatroban anticoa-gulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol, 2012, 78(3):330-335.
3.	Agarwal S, Ullom B, Al-Baghdadi Y, et al. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol, 2012, 28(1):106-110.
4.	陈怡琳, 施仲伟.抗凝新药利伐沙班临床研究进展.心血管病学进展, 2009, 30(5):810-813.
5.	Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol, 2008, 143(1):92-99.
6.	Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factorⅩa inhibitor. J Thromb Haemost, 2005, 3(3):514-521.
7.	Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol, 2006, 13(5):357-361.
8.	乔文豪, 王秀, 王佳丽, 等.抗血小板药物药理作用和临床应用的研究进展.安徽医药, 2014, 18(9):1621-1625.
9.	Divani AA, Zantek ND, Borhani-Haghighi A, et al. Antiplatelet therapy:aspirin resistance and all that jazz! Clin Appl Thromb Hemost, 2012, 19(1):5-18.
10.	刘宇, 曹清心, 赵仙先.阿司匹林抵抗的研究进展.国际心血管病杂志, 2014, 41(4):249-251.
11.	Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther, 2014, 141(1):69-78.
12.	张捷青, 吕迁洲.抗血小板药物——西洛他唑的临床应用进展.中国新药与临床杂志, 2013, 32(2):101-104.
13.	Squires H, Simpson E, Meng Y, et al. A systematic review and eco-nomic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in People with peripheral arterial disease. Health Technol Assess, 2011, 15(40):1-210.
14.	Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication:results of a randomized, multicenter trial. Arch Intern Med, 1999, 159(17):2041-2050.
15.	Geng DF, Liu M, Jin DM, et al. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation:a meta-analysis of 5 821 patients. Cardiology, 2012, 122(3):148-157.
16.	Heo SH, Lee JS, Kim BJ, et al. Effects of cilostazol against the prog-ression of carotid IMT in symptomatic ischemic stroke patients. J Neurol, 2013, 260(1):122-130.
17.	Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance. J Am Coll Cardiol, 2006, 47(1):27-33.
18.	Kajiwara I, Soejima H, Miyamoto S, et al. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. Thromb Res, 2011, 128(6):547-551.
19.	Cohen RA, Zitnay KM, Weisbrod RM. Accumulation of 5-hydroxy-tryptamine leads to dysfunction of adrenergic nerves in canine coronary artery following intimal damage in vivo. Circ Res, 1987, 61(6):829-833.
20.	任师颜, 王非, 钱松屹, 等.盐酸沙格雷酯治疗下肢动脉硬化闭塞症的疗效观察.中日友好医院学报, 2012, 26(3):142-144.
21.	Kumakura H, Kanai H, Araki Y, et al. Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting:intravascular ultrasound analysis. Ann Vasc Dis, 2009, 2(2):100-108.
22.	Chalouhi N, Jabbour P, Kung D, et al. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. Neuro-surgery, 2012, 71(3):710-714.
23.	汪忠镐, 章海.内皮细胞衬里人工血管的实验研究.心肺血管杂志, 1986, 5(4):52-57.
24.	[No authors listed]. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease:the Scandinavian Simva-statin Survival Study (4S). Lancet, 1994, 344(8934):1383-9138.
25.	中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南.中华心血管病杂志, 2007, 35(5):390-419.
26.	赵心彬, 倪敏, 陶霞.他汀类药物多效药理作用及其机制研究进展.药学实践杂志, 2013, 31(1):19-21.
27.	Davis HR, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis, 2011, 215(2):266-278.

1. Liuzzo G. Atherosclerosis:an inflammatory disease. Rays, 2001, 26(4):221-230.
2. Pappalardo F, Scandroglio AM, Potapov E, et al. Argatroban anticoa-gulation for heparin induced thrombocytopenia in patients with ventricular assist devices. Minerva Anestesiol, 2012, 78(3):330-335.
3. Agarwal S, Ullom B, Al-Baghdadi Y, et al. Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass. J Anaesthesiol Clin Pharmacol, 2012, 28(1):106-110.
4. 陈怡琳, 施仲伟.抗凝新药利伐沙班临床研究进展.心血管病学进展, 2009, 30(5):810-813.
5. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban-an oral, direct factor Xa inhibitor-has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol, 2008, 143(1):92-99.
6. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factorⅩa inhibitor. J Thromb Haemost, 2005, 3(3):514-521.
7. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol, 2006, 13(5):357-361.
8. 乔文豪, 王秀, 王佳丽, 等.抗血小板药物药理作用和临床应用的研究进展.安徽医药, 2014, 18(9):1621-1625.
9. Divani AA, Zantek ND, Borhani-Haghighi A, et al. Antiplatelet therapy:aspirin resistance and all that jazz! Clin Appl Thromb Hemost, 2012, 19(1):5-18.
10. 刘宇, 曹清心, 赵仙先.阿司匹林抵抗的研究进展.国际心血管病杂志, 2014, 41(4):249-251.
11. Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther, 2014, 141(1):69-78.
12. 张捷青, 吕迁洲.抗血小板药物——西洛他唑的临床应用进展.中国新药与临床杂志, 2013, 32(2):101-104.
13. Squires H, Simpson E, Meng Y, et al. A systematic review and eco-nomic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in People with peripheral arterial disease. Health Technol Assess, 2011, 15(40):1-210.
14. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication:results of a randomized, multicenter trial. Arch Intern Med, 1999, 159(17):2041-2050.
15. Geng DF, Liu M, Jin DM, et al. Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation:a meta-analysis of 5 821 patients. Cardiology, 2012, 122(3):148-157.
16. Heo SH, Lee JS, Kim BJ, et al. Effects of cilostazol against the prog-ression of carotid IMT in symptomatic ischemic stroke patients. J Neurol, 2013, 260(1):122-130.
17. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention:the role of dual drug resistance. J Am Coll Cardiol, 2006, 47(1):27-33.
18. Kajiwara I, Soejima H, Miyamoto S, et al. Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina. Thromb Res, 2011, 128(6):547-551.
19. Cohen RA, Zitnay KM, Weisbrod RM. Accumulation of 5-hydroxy-tryptamine leads to dysfunction of adrenergic nerves in canine coronary artery following intimal damage in vivo. Circ Res, 1987, 61(6):829-833.
20. 任师颜, 王非, 钱松屹, 等.盐酸沙格雷酯治疗下肢动脉硬化闭塞症的疗效观察.中日友好医院学报, 2012, 26(3):142-144.
21. Kumakura H, Kanai H, Araki Y, et al. Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting:intravascular ultrasound analysis. Ann Vasc Dis, 2009, 2(2):100-108.
22. Chalouhi N, Jabbour P, Kung D, et al. Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. Neuro-surgery, 2012, 71(3):710-714.
23. 汪忠镐, 章海.内皮细胞衬里人工血管的实验研究.心肺血管杂志, 1986, 5(4):52-57.
24. [No authors listed]. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease:the Scandinavian Simva-statin Survival Study (4S). Lancet, 1994, 344(8934):1383-9138.
25. 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南.中华心血管病杂志, 2007, 35(5):390-419.
26. 赵心彬, 倪敏, 陶霞.他汀类药物多效药理作用及其机制研究进展.药学实践杂志, 2013, 31(1):19-21.
27. Davis HR, Lowe RS, Neff DR. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis, 2011, 215(2):266-278.

Previous Article
下肢动脉硬化闭塞症的血管腔内治疗
Next Article
主髂动脉闭塞症外科和腔内治疗选择

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

下肢动脉硬化闭塞症的药物治疗

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content